LONDON, June 9, 2016 /PRNewswire/ --
European Respiratory & Pulmonary Diseases, 2016;2(1):Epub ahead of print DOI: http://doi.org/10.17925/ERPD.2016.02.01.1
Published recently in European Respiratory & Pulmonary Diseases, the peer-reviewed journal from touchRESPIRATORY, d'Ortho et al. discuss current and future use of adaptive servo-ventilation (ASV). ASV is a form of non-invasive positive airway pressure (PAP) therapy that differs from other PAP devices. It includes features to overcome both obstructive and central sleep-disordered breathing (SDB) events. In the Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnea by Adaptive Servo-Ventilation in Patients with Heart Failure (SERVE-HF) study, ASV significantly reduced SDB events in patients with systolic heart failure (HF) and predominant central sleep apnoea (CSA), but did not improve outcomes, and there was increased mortality risk in the ASV group. Although the SERVE-HF results represent a paradigm shift for ASV, they are only applicable to a small subset of ASV-treated patients, and there is no evidence suggesting that ASV use should stop altogether. There are a number of other indications and patient groups for whom ASV may be useful, effective and safe, including patients with treatment-emergent CSA, central apnoeas associated with long-term opioid therapy without alveolar hypoventilation, idiopathic Cheyne-Stokes respiration, after ischaemic stroke and those with HF with preserved ejection fraction. Additional research is required to better define the mechanism of increased risk associated with ASV identified in SERVE-HF and to more clearly characterise the specific patient phenotypes who benefit from ASV therapy.
The full peer-reviewed, open-access article is available here:
Disclosure: Marie-Pia d'Ortho has received grants from Fisher & Paykel Healthcare and ADEP Assistance, grants and personal fees from ResMed, Philips Respironics and IP Sante and personal fees and non-financial support from Vitalaire. Holger Woehrle is an employee of ResMed Germany. Michael Arzt has received unrestricted grant support from Philips Home Healthcare Solutions, ResMed Germany and the German Foundation for Cardiac Research (Deutsche Stiftung für Herzforschung); he is also the holder of an endowed professorship from the Free State of Bavaria at the University of Regensburg that was donated by Philips Home Healthcare Solutions and ResMed Germany.
touchRESPIRATORY (a division of Touch Medical Media) publishesEuropean Respiratory & Pulmonary Diseases, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of respiratory and pulmonary diseases. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
For inquires please contact:
Carla Denaro - Managing Editor
Providing practical opinion to support best practice for busy healthcare professionals.